Download PDF
Pharmacopsychiatry 2002; 35(6): 239-243
DOI: 10.1055/s-2002-36394
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Prescribing Second-Generation Antipsychotics and the Evolving Standard of Care in Italy

C. Barbui1 , A. Danese1 , G. Guaiana1 , L. Mapelli1 , L. Miele1 , E. Monzani1 , M. Percudani on behalf of the Study Group1
  • 1Laboratory of Epidemiology and Social Psychiatry, ”Mario Negri” Institute for Pharmacological Research, Milan, Italy
E. Caverzasi, A. Danese, P. Brambilla, L. Fagioli, C. Civardi, S. Astori (Laboratorio di Valutazione dell’Assistenza, Dipartimento di Scienze Sanitarie Applicate e Psicocomportamentali, Università di Pavia); C.M. Cornaggia, L. Mapelli (Clinica Psichiatrica, Università degli Studi di Milano-Bicocca, Ospedale S.Gerardo, Monza); L. Miele, S. Gianetti, A. Ruggeri (Clinica Psichiatrica, Università degli Studi di Milano, Ospedale Maggiore I.R.C.C.S.); M. Percudani, P. Castiglioni, D. Merckling, R. Colombo (Unità Operativa di Psichiatria, Legnano); E. Amato, I. Rota Graziosi, M. Pellegril, G. Tarchini (Centra Psico-Sociale Bergamo Orientale, Ospedali Riuniti di Bergamo); R. Corsa, A. Pagliara, E. Cavallaro, V. Restelli (Centro Psico-Sociale Bergamo Occidentale, Ospedali Riuniti di Bergamo); E. Monzani, M. Frova, M. Alessandri, T. Melorio (Dipartimento di Salute Mentale, Azienda Ospedaliera Niguarda Ca’ Granda, Milano)
Further Information

Publication History

Received: 13.7.2001 Revised: 28.11.2001

Accepted: 31.1.2002

Publication Date:
20 December 2002 (online)

Also available at
    Permissions and Reprints

The present study was carried out to investigate the routine use of second-generation antipsychotic drugs in the Italian psychiatric care system. Seven outpatient psychiatric services enrolled a consecutive case series of patients who were being treated, or had started treatment, with clozapine, olanzapine, risperidone, or quetiapine. Information on sociodemographic and clinical variables, current psychotropic drug use, side-effects and past use of typical drugs was collected. In addition, patient symptoms and functional status were evaluated by the Health of the Nation Outcome Scale. Patients receiving off-label prescribing of second-generation antipsychotics were identified. A total of 209 patients were collected. In comparison with patients receiving other second-generation antipsychotics, living in residential facilities, unemployment, long psychiatric histories, and problems with activities of daily living and living conditions were more common in clozapine-treated patients. Nearly 80 % of patients receiving clozapine had schizophrenia compared to less than 50 % of those receiving other second-generation antipsychotics. Overall, 109 patients (52 %) received off-label prescriptions of second-generation antipsychotic drugs. This survey indicates that clozapine was mostly reserved for severe cases and poor responders; the high rate of off-label prescriptions highlights the gap existing between recommendations derived from randomised clinical trials and the current use of drugs.

References

  • 1 Barbui C, Campomori A, Mezzalira L, Da Cas R, Garattini S. Psychotropic drug use in Italy 1984 - 1999: the impact of a change in reimbursement status.  Int Clin. Psychopharmacol 2001;  16 227-233
    PubMedGoogle Scholar
  • 2 Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomised trials.  Am J Psychiatry. 2001;  158 518-526
    Google Scholar
  • 3 Curtis R, Beevor A. Health of the Nation Outcome Scales. In Wing JK, editor Measurement for Mental Health. London; College Research Unit 1995
    Google Scholar
  • 4 Fleischhacker W W. Pharmacological treatment of schizophrenia: a review. In Maj M, Sartorius N, editors Schizophrenia. Vol. 2. WPA Series: Evidence and Experience in Psychiatry. John Wiley & Sons 1999: 75-107
    Google Scholar
  • 5 Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service.  Eur Psychiatry. 2000;  15 220-226
    CrossrefPubMedGoogle Scholar
  • 6 Geddes J, Freemantle N, Harrison P, Bebbington P for the National Schizophrenia Guideline Development G roup. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.  BMJ. 2000;  321 1371-1376
    CrossrefPubMedGoogle Scholar
  • 7 Kapur S, Remington G. Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects.  BMJ. 2000;  321 1360-1361
    CrossrefPubMedGoogle Scholar
  • 8 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials.  Schizophr Res. 1999;  35 51-68
    CrossrefPubMedGoogle Scholar
  • 9 Lowe-Ponsford F, Baldwin D. Off-label prescribing by psychiatrists.  Psychiatric Bull. 2000;  24 415-417
    PubMedGoogle Scholar
  • 10 Meltzer H Y. Treatment-resistant schizophrenia - the role of clozapine.  Curr Med Res Opinion. 1997;  14 1-20
    PubMedGoogle Scholar
  • 11 Miller A L, Chiles J A, Chiles J K. et al . Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.  J Clin Psychiatry. 1999;  60 649-657
    PubMedGoogle Scholar
  • 12 StataCorp. Stata Statistical Software: Release 4. College Station, TX: Stata Corporation. 1995
    Google Scholar
  • 13 Stein G S. Usefulness of the Health of the Nation Outcome Scales.  Br J Psychiatry. 1999;  174 375-377
    PubMedGoogle Scholar
  • 14 Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomised trials.  Am J Psychiatry. 1999;  156 990-999
    PubMedGoogle Scholar
  • 15 Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker W W. Off-label use of antipsychotic drugs.  J Clin Psychopharmacol. 2000;  20 695-698
    CrossrefPubMedGoogle Scholar
  • 16 WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC Classification and DDD Assignment. WHO Oslo; 1996
    Google Scholar

Dr. Corrado Barbui

Dept of Medicine and Public Health

Psychiatry Section

University of Verona

Ospedale Policlinico

37134 Verona

Italy

Phone: +39 (045) 807 44 41

Fax: +39 (045) 585 871

Email: corrado.barbui@univr.it

      >